Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5efd7678df08428d9c18324e7b243fe5,
title = "The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer",
abstract = "This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy.",
author = "Mikkel Bandak and Lise Aksglaede and Anders Juul and Mikael R{\o}rth and Gedske Daugaard",
note = "Copyright {\circledC} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.ejca.2011.05.026",
language = "English",
volume = "47",
pages = "2585--91",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",
number = "17",

}

RIS

TY - JOUR

T1 - The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer

AU - Bandak, Mikkel

AU - Aksglaede, Lise

AU - Juul, Anders

AU - Rørth, Mikael

AU - Daugaard, Gedske

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy.

AB - This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy.

U2 - 10.1016/j.ejca.2011.05.026

DO - 10.1016/j.ejca.2011.05.026

M3 - Journal article

VL - 47

SP - 2585

EP - 2591

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

IS - 17

ER -

ID: 32776864